Data Set Group2: EPFL/LISP BXD CD Muscle Affy Mouse Gene 1.0 ST (Nov12)

Data Set: EPFL/LISP BXD HFD Muscle Affy Mouse Gene 1.0 ST (Dec11) RMA GN Accession: GN380 GEO Series: GSE60151 Title: An evolutionarily conserved role for the aryl hydrocarbon receptor in the regulation of movement Organism: Mouse (Mus musculus, mm10) Group: BXD Tissue: Muscle mRNA Dataset Status: Public Platforms: Affy Mouse Gene 1.0 ST (GPL6246) Normalization: RMA

Contact Information Johan Auwerx Ecole Polytechnique Federale de Lausanne Bâtiment AI, Chambre 1351 Lausanne, Lausanne 1015 Switzerland Tel. +41 216930951 admin.auwerx@epfl.ch Website Download datasets and supplementary data files GN380_MeanDataAnnotated_rev081815.txt (N/A) GN380_StdError_rev081815.txt (N/A)

Specifics of this Data Set:

None

Summary:

Highlights Inhibition of poly(ADP-ribose) polymerases (PARPs) enhances endurance performance Inhibition of PARPs improves mitochondrial function in skeletal muscle Parp-1 correlates with energy expenditure in heterogeneous mouse populations Genetic and acquired mitochondrial defects can be rescued by PARP inhibition We previously demonstrated that the deletion of the poly(ADP-ribose)polymerase (Parp)-1 gene in mice enhances oxidative metabolism, thereby protecting against diet-induced obesity. However, the therapeutic use of PARP inhibitors to enhance mitochondrial function remains to be explored. Here, we show tight negative correlation between Parp-1 expression and energy expenditure in heterogeneous mouse populations, indicating that variations in PARP-1 activity have an impact on metabolic homeostasis. Notably, these genetic correlations can be translated into pharmacological applications. Long-term treatment with PARP inhibitors enhances fitness in mice by increasing the abundance of mitochondrial respiratory complexes and boosting mitochondrial respiratory capacity. Furthermore, PARP inhibitors reverse mitochondrial defects in primary myotubes of obese humans and attenuate genetic defects of mitochondrial metabolism in human fibroblasts and C. elegans. Overall, our work validates in worm, mouse, and human models that PARP inhibition may be used to treat both genetic and acquired muscle dysfunction linked to defective mitochondrial function.

About the cases used to generate this set of data:

About the tissue used to generate this set of data:

The muscle datasets are all generated from quadriceps muscles. These animals were born, raised, phenotyped, and sacrificed at the EPFL in the group of Johan Auwerx. Animals were all approximately 29 weeks of age and were all male. Chow diet cohorts ("CD") were fed Harlan 2018 (6% kcal/fat, 20% protein, 74% carbohydrate). High fat diet ("HFD") cohorts were fed Harlan 06414 (60% kcal/fat, 20% protein, 20% carbohydrate). Animals adjusted to the diet for 8 weeks, and then an intensive phenotyping metabolic phenotyping protocol was followed from 16 to 24 weeks of age (respiration, cold tolerance, oral glucose response, VO2max exercise, voluntary exercise, basal activity). Animals were communally housed until the last 5 weeks of the experiment, when the animals could rest. After an overnight fasting and isoflurane anesthesia, animals were sacrificed following a blood draw and perfusion. Quadriceps were cut horizontally from the femur bone and then frozen in liquid nitrogen for an extended period. Cohorts were sacrificed in a staggered fashion, with approximately 1 cohort per week over a period of 2-3 years. mRNA was prepared for the quadriceps in two distinct batches approximately one year apart (Batch 1: late spring 2011; Batch 2: late spring 2012). Microarrays were run on the samples in two distinct batches shortly after being prepared and received.   Batch 1 is the following cohorts: C57HFD 100HFD 62HFD 83CD C57CD 70CD 75CD 96CD 44HFD 45CD 61HFD 73CD DBACD 45HFD 63CD 87CD 89CD 90HFD 62CD 75HFD DBAHFD 44CD 66CD 87HFD 66HFD 55HFD 55CD 70HFD 51CD 83HFD 80CD 51HFD 73HFD 96HFD 61CD 90CD 80HFD 63HFD   Batch 2 is the following cohorts: 49HFD 43CD 50CD 89HFD 84CD 100CD 81HFD 98HFD 103CD 68CD 79CD 99CD 71CD 48HFD 64HFD 84HFD 101CD 103HFD 60CD 79HFD 68HFD 48CD 71HFD 65CD 85HFD 99HFD 81CD 49CD 56HFD 97CD 97HFD 92CD 69CD 64CD 69HFD 56CD 65HFD 43HFD 85CD 95CD 98CD   For all cohorts in these datasets, roughly 2-5 animals (typically around 4) had mRNA extracted separately, and then mRNA were pooled equally for each individual in a cohort. After the mRNA were pooled for the individuals within a cohort—a cohort meaning the same diet, sex, strain, and littermate—the samples were purified using RNEasy.    Once both cohorts were completed, the two batches were re-normalized together using RMAExpress and the two batches were logged and z-normalized. The mean was set to 8 units and standard deviation was set to 2 units for all samples. This removes negative values from the samples, and reduces the batch effect between the two groups.

About the array platform:

About data values and data processing:

Notes:

More information will be available soon

Experiment Type:

Contributor:

Citation:

Pirinen et al., Cell Metabolism 2014, Pharmacological Inhibition of Poly(ADP-Ribose) Polymerases Improves Fitness and Mitochondrial Function in Skeletal Muscle. Citation: The chow diet data were first published in the paper "Pharmacological Inhibition of Poly(ADP-Ribose) Polymerases Improves Fitness and Mitochondrial Function in Skeletal Muscle" in June 2014. The complete dataset was published in the paper "An evolutionarily conserved role for the aryl hydrocarbon receptor in the regulation of movement" in September 2014. If you are using exclusively the chow diet data, please cite the former paper, but if you are using both diets, or if you are only using high fat data, please cite just the latter paper. The complete phenotyping data for these individuals was published in 2016 in the paper "Systems proteomics of liver mitochondria function". Note that the animals used in that 2016 paper are exactly the same ones as the September 2014 paper. Note that in addition to quadriceps transcriptome data on these individuals, liver mRNA, liver SRM proteomics (200 proteins), liver SWATH proteomics (2600 proteins), liver metabolomics, plasma metabolomics (under "Phenotypes" in GeneNetwork), brown adipose mRNA (CD only), and heart mRNA are all published and openly available here in GeneNetwork. Liver and plasma lipidomics, gastrointestinal mRNA and white adipose tissue mRNA have also been completed and are expected to be published in the future but remain under active work (January 2018 note).

Data source acknowledgment:

Study Id:

137

• The UT Center for Integrative and Translational Genomics
• NIGMS Systems Genetics and Precision Medicine project (R01 GM123489, 2017-2021)
• NIDA NIDA Core Center of Excellence in Transcriptomics, Systems Genetics, and the Addictome (P30 DA044223, 2017-2022)
• NIA Translational Systems Genetics of Mitochondria, Metabolism, and Aging (R01AG043930, 2013-2018)
• NIAAA Integrative Neuroscience Initiative on Alcoholism (U01 AA016662, U01 AA013499, U24 AA013513, U01 AA014425, 2006-2017)
• NIDA, NIMH, and NIAAA (P20-DA 21131, 2001-2012)
• NCI MMHCC (U01CA105417), NCRR, BIRN, (U24 RR021760)